Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.COWbVb-l.js ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.

The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...

So get your questions in now for Art and he will be with you between 4pm and 5pm GMT (11am to 12pm ET) to answer as many as he can ...

"The last four or five games here, we’re in those games. So it’s not like there have been just horrible blowouts." ...

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...

A Gardner man is remembering his friend Alexandr Kirsanov, who was killed in the collision between American Airlines 5342 and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regulus (RGLS – Research Report) and Roche ...